Skip to main content
The Canadian Veterinary Journal logoLink to The Canadian Veterinary Journal
. 2018 May;59(5):545–547.

Demodicosis: New treatment, common misdiagnosis

Michael G Charach 1,✉
PMCID: PMC5901858  PMID: 29904212

The treatment of demodicosis took a major step forward 2 years ago when a study demonstrated that fluralaner (Bravecto; Intervet-Merck Animal Health, Kirkland, Quebec), was very effective in the successful resolution of generalized demodicosis in 8 dogs over 1 year of age (1). The study did not indicate how many dogs had juvenile-onset or adult-onset demodicosis. All dogs were treated once with a minimum oral dosage of 25 mg/kg body weight (BW). The single treatment resulted in all 8 dogs being mite-free on skin scraping on day 56 and day 84. All but 1 dog showed > 90% hair regrowth by 12 weeks after the initial treatment (1).

A second study (2) involved treatment of 4 dogs with generalized demodicosis orally with 2.5 mg/kg BW afoxolaner (NexGard; Merial, Duluth, Georgia, USA) at monthly intervals for 3 consecutive months. Two dogs had juvenile onset and the other 2 dogs had adult onset generalized demodicosis. All 4 dogs were mite-free at 8 and 12 weeks based on skin scrapings (2). Afoxolaner (NexGard, Merial) was also used successfully in another group of 8 dogs with generalized demodicosis (3). They were treated with a minimum of 2.5 mg/kg BW on days 0, 14, 28, and 56. The bi-weekly treatments with NexGard were based on pharmacokinetic properties of afloxolaner, in order to rapidly achieve a steady-state concentration in the blood and this was considered safe based on target animals’ safety studies. The percentages reduction in mite counts were 99.2%, 99.9%, and 100% on days 28, 56, and 84, respectively (3).

In another study (4), 16 dogs over the age of 6 mo with generalized demodicosis were all successfully treated orally with 2 mg/kg BW of sarolaner (Simparica; Zoetis, Patsippany, New Jersey, USA) at monthly intervals for 3 months. Skin scrapings were negative in all 16 dogs by day 44 and thereafter.

All 3 drugs are systemic insecticides and acaricides belonging to the isoxazoline class of parasiticides with selective inhibition of arthropod gamma-aminobutyric acid and L-glutamate-gated chloride channels. Fluralaner and sarolaner can be used in dogs as young as 6 months and afoxolaner can be used in dogs as young as 8 weeks of age. These drugs are not labelled for use for demodicosis (5).

These drugs are considered safe with rare adverse effects including vomiting, diarrhea, anorexia, lethargy, and flatulence. Specific considerations include:

  • Afoxolaner should be used with caution in dogs with a history of seizures. It does not have to be given with food for adequate absorption.

  • Sarolaner may cause neurologic signs, including tremors, ataxia, and seizures (4).

  • Fluralaner must be given with food for adequate absorption (3).

We have used Bravecto on many occasions over the last 1 1/2 years and have not seen any treatment failures. Only 1 dog vomited after taking the drug, and the manufacturer stated that if vomiting occurs after 3 hours of taking the drug, adequate absorption has occurred and re-administration is not necessary. The manufacturer recommends repeating the medication if vomiting occurs within 3 hours of administration. The client, therefore, should record the time at which the drug is given in the rare event that vomiting does occur. The manufacturer will consider giving a free replacement, if this happens. The high degree of efficacy, low cost, relative safety, and ease of use, mean better owner compliance and make the isoxazoline class of drugs the therapy of choice for demodicosis.

The best treatment is of no use if one doesn’t make a correct diagnosis of demodicosis. Unfortunately the misdiagnosis of demodicosis is too common. The consequences of missing a diagnosis of demodicosis can be devastating to the patient and the client. Dogs may suffer from severe deep pyodermas that worsen over months of antibiotic treatment that fail because of lack of treatment for Demodex. The patient is often subjected to a number of symptomatic therapies to no avail. To make matters worse these patients may receive systemic or topical corticosteroids that will cause the demodicosis and pyoderma to become worse.

There are 2 main causes of misdiagnoses. The minority stem from the skin scraping test failing to reveal the presence of mites. It is imperative that a false negative be avoided by squeezing the skin before scraping to expel the mites from the follicle. Another way to retrieve the mites from the follicle is to epilate some hairs from the follicles and view the base of the hairs. Multiple scrapings, especially from the face, paws, and legs are essential. The skin scraping test is very reliable, as long as these techniques are used. Deep pyoderma of the paws with the associated swelling may make it more difficult to extrude the mites to the surface, so multiple scrapings or a biopsy may be necessary to make the diagnosis, although this is rare. We have seen cases in which a patient had negative scrape tests done by multiple veterinarians, followed by failure of the patient to respond to antibiotics; we then examined skin scrapings and found them positive (6). It’s always beneficial to re-scrape dogs that are not responding to antibiotics.

A major source of misdiagnosis of demodicosis is simply not including it on the list of differential diagnoses, so skin scrapings are not performed. Veterinarians appear to be generally effective at diagnosing juvenile onset demodicosis (JOD), but not as effective diagnosing adult onset demodicosis (AOD). This is the area in which we see the most misdiagnoses. A number of underlying diseases and treatments (Table 1) may suppress the immune system predisposing the patient to demodicosis. The use of corticosteroids and hyperadrenocorticism are 2 major sources (7–9). Once the likely cause of adult-onset demodicosis has been diagnosed, eliminating the cause of immunosuppression is essential for a positive outcome.

Table 1.

Causes of adult onset demodicosis in 41 dogs (3).

Drug-induced 39%
 Corticosteroids in allergy patients 24%
 Chemotherapy/neoplasia immune-mediated disease 15%
Endocrine disorder 31%
 Hyperadrenocorticism 19%
 Hypothyroidism 12%
Unidentified 30%

Neoplasia in very old dogs may be asymptomatic, such as in patients with small occult tumors and demodicosis as a paraneoplastic syndrome (8). This association may be under-reported as the malignancy may not become clinical for many months after the demodicosis is diagnosed. Therefore older dogs with Demodex may be classified as “unidentified”(Table 1). Some of the “hypothyroid” dogs that have demodicosis may have euthyroid sick syndrome due to occult tumors rather than having the hypothyroidism as the reason that demodicosis developed.

Of 431 dogs with demodicosis presented to a teaching hospital from 2000 to 2016, 225 (< 18 months) had JOD, 139 (> 48 months) had AOD and 67 could not be classified. The English bull dog and Staffordshire terrier were at increased odds of developing JOD. The JOD group had superficial pyoderma (n = 107), deep pyoderma (n = 22), or yeast dermatitis (n = 15, 6/15 had concurrent allergic disease) as secondary issues. Allergic disease was diagnosed before the JOD in 50 dogs, 17 of which had received corticosteroids. The AOD group had superficial pyoderma (n =73), deep pyoderma (n = 36), and yeast dermatitis (n = 30, 20 with concurrent allergic disease). At the time of diagnosis of AOD, 59% (82 of 139) had been diagnosed with a concurrent disease and 39% (55 of 139) had been treated with immunosuppressive therapy. The diseases most commonly identified concurrently with AOD (n = 139) were allergic disease (n = 57), hypothyroidism (n = 15), neoplasia (n = 14) and hyperadrenocortism (n = 6). Of the 57 allergic dogs, 29 had received immunosuppressive therapy [systemic (n = 26), topical (n = 3) corticosteroids and 2 had received oclacitinib maleate (Apoquel, Zoetis)]. The remaining dogs with allergic disease (28 of 57) had not received immunosuppressive medications (10).

Relapse or recurrence of demodicosis that were followed long-term and treated with various miticidal medications occurred in 11% (22 of 194). Incurable infestations occurred in just 5.2% (10 of 194), requiring long-term continuous therapy.

The clinical presentation of generalized demodicosis is highly variable (Figure 1). Usually, patchy, regional, multifocal, or diffuse alopecia is seen with variable erythema, silvery grayish scaling, and papules. Follicular hyperkeratosis is often marked; follicular openings are usually accentuated and plugged resulting in follicular casts or comedones. Some dogs may only manifest seborrheic changes. The skin may become hyperpigmented, lichenified, pustular, eroded, crusted, or ulcerated from secondary superficial and deep pyoderma. Pododemodicosis may appear through interdigital pruritus, pain, erythema, alopecia, hyperpigmentation, lichenification, scaling, swelling, crust papules, bullae, and draining tracts. Peripheral lymphadenopathy is common. Systemic signs (fever, depression, anorexia) may be seen if secondary sepsis develops (8,9). It should be stressed that demodicosis is one of the most common causes, if not the most common cause of deep pyoderma, especially of the paws and face of dogs of any age. Every dog showing any of these signs should be thoroughly screened for Demodex mites. With a skin scraping, a single pill, and treatment of secondary infections, we can now prevent months of suffering and inappropriate costly therapy that will fail, when the diagnosis of demodicosis is missed.

Figure 1.

Figure 1

Twenty-two-month-old Neapolitan mastiff with generalized demodicosis, onset at 10 months of age, that failed to respond to antibiotics.

Uncomplicated demodicosis is not considered very pruritic. Secondary pyoderma will contribute to pruritus. Secondary Malassezia has been seen as causing more intense pruritus in some demodicosis patients. Cytology would be helpful in the very pruritic Demodex cases that may also have Malassezia dermatitis. If the patient had been treated for allergies with corticosteroids then some of the pruritus might still be due to an underlying allergy.

Footnotes

Guest author for the Canadian Academy of Veterinary Dermatology (CAVD).

The CAVD is a not-for-profit organization that promotes veterinary dermatology in Canada and provides continuing education for veterinarians, animal health technicians/technologists and veterinary students. The CAVD welcomes applications for membership (www.cavd.ca).

Use of this article is limited to a single copy for personal study. Anyone interested in obtaining reprints should contact the CVMA office (hbroughton@cvma-acmv.org) for additional copies or permission to use this material elsewhere.

References

  • 1.Fourie JJ, Lienberg JE, Horak IG, Taenzler J, Heckeroth AR, Frénais R. Efficacy of orally administered fluralaner (Bravecto) or topically applied imidacloprid/moxidectin (Advocate) against generalized demodicosis in dogs. Parasit Vectors. 2015;8:187. doi: 10.1186/s13071-015-0775-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Chavez F. Case Report of afoxolaner treatment for canine demodicosis in four dogs naturally infected with Demodex canis. Intern J Appl Res Vet Med. 2016;14:123–127. [Google Scholar]
  • 3.Beugnet F, Halos L, Larsen D, de Vos C. Efficacy of oral afoxolaner for the treatment of canine generalized demodicosis. Parasite. 2016;23:14. doi: 10.1051/parasite/2016014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Six RH, Becskei C, Mazaleski MM, et al. Efficacy of sarolaner, a novel oral isoxazoline, against two common mite infestations in dogs: Demodex spp. and Otodectes cynotis. Vet Parasitol. 2016;222:62–66. doi: 10.1016/j.vetpar.2016.02.027. [DOI] [PubMed] [Google Scholar]
  • 5.Koch SH. Dermatology details and updates on the management of canine demodicosis. Today’s Veterinary Practice. 2017 Jan-Feb;7:77–85. [Google Scholar]
  • 6.Robson DC. Never miss another case of canine demodicosis? It just might be possible. [Last accessed March 8, 2018]. Available from: https://barvets.com/canine-demodicosis/
  • 7.Duclos DD, Jeffers JG, Shanley KJ. Prognosis for treatment of adult onset demodicosis in dogs: 32 cases (1979–1990) J Am Vet Med Assoc. 1994;204:616–619. [PubMed] [Google Scholar]
  • 8.Hnilica KA, Patterson AP. Small Animal Dermatology. Knoxville, Tennessee: Elsevier; 2016. Parasitic skin disorders; pp. 132–172. [Google Scholar]
  • 9.Miller WH, Griffin CE, Campbell KK. Small Animal Dermatology. 7th ed. St. Louis, Missouri: Elsevier; 2013. Parasitic skin disease; pp. 284–342. [Google Scholar]
  • 10.Bowden DG, Outerbridge CA, Kissel MB, Baron JN, White SD. Canine demodicosis: A retrospective study of a veterinary hospital population in California, USA (2000–2016) Vet Dermatol. 2018 Feb;29(1):19–e10. doi: 10.1111/vde.12484. [DOI] [PubMed] [Google Scholar]

Articles from The Canadian Veterinary Journal are provided here courtesy of Canadian Veterinary Medical Association

RESOURCES